继发性噬血性淋巴组织细胞增生症诊断和治疗新进展
Recent Advances in Diagnosis and Treatment of Secondary Hemophagocytic Lymphohistiocytosis
DOI: 10.12677/MD.2014.41001, PDF, HTML, 下载: 2,593  浏览: 9,221  科研立项经费支持
作者: 欧丹艳, 罗建明, 唐利娟：广西医科大学第一附属医院，南宁
关键词: 噬血性淋巴组织细胞增生症；继发性；发病机制；诊断；治疗；Hemophagocytic Lymphohistiocytosis； Secondary； Pathogenesis； Diagnosis； Treatment
摘要: 噬血性淋巴组织细胞增生症(Hemophagocytic Lymphohistiocytosis, HLH)是一种少见的威胁生命的疾病，它是由过度增生的活化淋巴细胞和巨噬细胞产生大量细胞因子所造成的过度炎症反应。近年来在HLH的诊断和治疗上取得了一定的进展，但重症HLH的死亡率依然较高。HLH一般分为原发性和继发性。与原发性HLH相比，继发性HLH更常见，病因复杂，预后差异较大。本文对继发性HLH的诊断与治疗研究现状作一综述。
Abstract: Hemophagocytic lymphohistiocytosis (HLH) is a rare and potentially fatal syndrome. It is associated with uncontrolled proliferation of activated lymphocytes and macrophages which secrete great amounts of inflammatory cytokines. Despite progress in diagnosis and treatment, severe HLH still has a high mortality rate. HLH is classified as two subgroups: primary HLH and secondary HLH. Secondary HLH is involved in severe infections, malignancies and autoimmune diseases. This review seeks to update readers on current status and research progress related to this uncommon but life-threatening disease.
文章引用：欧丹艳, 罗建明, 唐利娟. 继发性噬血性淋巴组织细胞增生症诊断和治疗新进展 [J]. 医学诊断, 2014, 4(1): 1-6. http://dx.doi.org/10.12677/MD.2014.41001

参考文献

[1] Janka, G.E. (2007) Hemophagocytic syndromes. Blood Reviews, 21, 245-253.
[2] Filipovich, A.H. (2006) Hemophagocyticlymphohistiocytosis and related disorders. Current Opinion in Allergy and Clinical Immunology, 6, 410-415.
[3] Janka, G. (2009) Hemophagocyticlymphohistiocytosis: When the immune system runs amok. Clinical Pediatrics, 221, 278-285.
[4] Machaczka, M., Vaktnäs, J., Klimkowska, M., et al. (2011) Malignancy-associated hemophagocyticlymphohistiocytosis in adults: A retrospective population-based analysis from a single center. Leukemia & Lymphoma, 52, 613-619.
[5] Gokce, M., Unal, O., Hismi, B., et al. (2012) Secondary hemophagocytosis in 3 patients with organic acidemia involving propionate metabolism. Journal of Pediatric Hematology/Oncology, 29, 92-98.
[6] Abdelkefi, A., Ben Jamil, W., Torjman, L., et al. (2009) Hemophagocytic syndrome after hematopoietic stem cell transplantation: A prospective observational study. International Journal of Hematology, 89, 368-373.
[7] Gurkan, A., Yakupoglu, U., Yavuz, A., et al. (2006) Hemophagocytic syndrome in kidney transplant recipients: Report of four cases from a single center. Acta Haematologica, 116, 108-113.
[8] Maakaroun, N.R., Moanna, A., Jacob, J.T., et al. (2010) Viral infections associated with haemophagocytic syndrome. Reviews in Medical Virology, 20, 93-105.
[9] Rouphael, N.G., Talati, N.J., Vaughan, C., et al. (2007) Infections associated with haemophagocytic syndrome. The Lancet Infectious Diseases, 7, 814-822.
[10] Ravelli, A. (2002) Macrophage activation syndrome. Current Opinion in Rheumatology, 14, 548-552.
[11] Ramanan, A.V. and Schneider, R. (2003) Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. The Journal of Rheumatology, 30, 401-403.
[12] Bryceson, Y.T., Pende, D., Maul-Pavicic, A., et al. (2012) A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood, 119, 2754-2763.
[13] Grom, A.A., Villanueva, J., Lee, S., et al. (2003) Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. Journal of Pediatrics, 142, 292-296.
[14] Maruyama, J. and Inokuma, S. (2010) Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. Journal of Pediatrics, 37, 967-973.
[15] Shimizu, M., Yokoyama, T., Yamada, K., et al. (2010) Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology, 49, 1645-1653.
[16] Krebs, P., Crozat, K., Popkin, D., Oldstone, M.B. and Beutler, B. (2011) Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice. Blood, 117, 6582-6588.
[17] Behrens, E.M., Canna, S.W., Slade, K., Rao, S., Kreiger, P.A., Paessler, M., Kambayashi, T. and Koretzky, G.A. (2011) Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. Journal of Clinical Investigation, 121, 2264-2277.
[18] Yanagimachi, M., Naruto, T., Miyamae, T., et al. (2011) Association of IRF5 polymorphisms with susceptibility to macrophage activation syndrome in patients with juvenile idiopathic arthritis. Journal of Rheumatology, 38, 769-774.
[19] Haddad, E., Sulis, M.L., Jabado, N., Blanche, S., Fischer, A. and Tardieu, M. (1997) Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis. Blood, 89, 794-800.
[20] Arico, M., Janka, G., Fischer, A., et al. (1996) Hemophagocytic lymphohistiocytosis. Report of 122 children from the in-ternational registry. FHL study group of the histiocyte society. Leukemia, 10, 197-203.
[21] Henter, J.I., Horne, A.C., Aricó, M., et al. (2007) HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatric Blood & Cancer, 48, 124-131.
[22] 中华医学会儿科学分会血液学组 (2012) 噬血细胞性淋巴组织细胞增生症诊疗建议. 中华儿科杂志, 11, 821825.
[23] Ravelli, A., Viola, S., De Benedetti, F., Magni-Manzoni, S., Tzialla, C. and Martini, A. (2001) Dramatic efficacy of cyclosporine A in macrophage activation syndrome. Clinical and Experimental Rheumatology, 19, 108.
[24] Jordan, M.B., Allen, C.E., Weitzman, S., Filipovich, A.H. and McClain, K.L. (2011) How I treat hemophagocytic lymphohistiocytosis. Blood, 118, 4041-4052.
[25] Vastert, S.J., Kuis, W. and Grom, A.A. (2009) Systemic JIA: New developments in the understanding of the pathophysiology and therapy. Best Practice & Research Clinical Rheumatology, 23, 655-664.
[26] Milone, M.C., Tsai, D.E., Hodinka, R.L., Silverman, L.B., Malbran, A., Wasik, M.A. and Nichols, K.E. (2005) Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood, 105, 994-996.
[27] Balamuth, N.J., Nichols, K.E., Paessler, M. and Teachey, D.T. (2007) Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis. Journal of Pediatric Hematology/Oncology, 29, 569-573.
[28] Sung, L., King, S.M., Carcao, M., Trebo, M. and Weitzman, S. (2002) Adverse outcomes in primary hemophagocytic lymphohistiocytosis. Journal of Pediatric Hematology/Oncology, 24, 550-554.
[29] Henter, J.I., Arico, M., Egeler, M., Elinder, G., Favara, B.E., Filipovich, A.H., Gadner, H., Imashuku, S., Janka-Schaub, G., Komp, D., Ladisch, S. and Webb, D. (1997) HLH-94: A treatment protocol for hemophagocytic lymphohistiocytosis. Medical and Pediatric Oncology, 28, 342-347.
[30] Trottestam, H., Horne, A., Aricò, M., et al., Histiocyte Society (2011) Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: Long-term results of the HLH-94 treatment protocol. Blood, 118, 4577-4584.
[31] Ohga, S., Kudo, K., Ishii, E., Honjo, S., Morimoto, A., Osugi, Y., Sawada, A., Inoue, M., Tabuchi, K., Suzuki, N., Ishida, Y., Imashuku, S., Kato, S. and Hara, T. (2010) Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan. Pediatric Blood & Cancer, 54, 299-306.
[32] Ishii, E., Ohga, S., Imashuku, S., et al. (2007) Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. International Journal of Hematology, 86, 58-65.
[33] Trottestam, H., Berglöf, E., Horne, A., Onelöv, E., Beutel, K., Lehmberg, K., Sieni, E., Silfverberg, T., Aricò, M., Janka, G. and Henter, J.I. (2012) Risk factors for early death in children with haemophagocytic lymphohistiocytosis. Acta Paediatrica, 101, 313-318.
[34] 陆文娴, 罗建明 (2012) 儿童噬血细胞性淋巴组织细胞增生症的预后因素分析. 中国当代儿科杂志, 8, 593-597.